Q2 EPS Estimate for Acurx Pharmaceuticals Raised by Analyst

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Analysts at HC Wainwright boosted their Q2 2026 earnings estimates for shares of Acurx Pharmaceuticals in a report issued on Tuesday, May 12th. HC Wainwright analyst M. Keller now expects that the company will earn ($0.42) per share for the quarter, up from their previous estimate of ($0.63). The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.94) EPS and FY2027 earnings at ($1.76) EPS.

A number of other equities analysts also recently issued reports on the stock. Wall Street Zen upgraded shares of Acurx Pharmaceuticals to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Acurx Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Stock Performance

ACXP stock opened at $1.99 on Thursday. The company has a fifty day moving average of $3.08 and a 200-day moving average of $3.24. The stock has a market capitalization of $5.69 million, a PE ratio of -0.49 and a beta of -2.09. Acurx Pharmaceuticals has a one year low of $1.33 and a one year high of $21.00.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03).

Hedge Funds Weigh In On Acurx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC purchased a new position in Acurx Pharmaceuticals during the 4th quarter valued at about $103,000. Armistice Capital LLC purchased a new position in Acurx Pharmaceuticals during the 2nd quarter valued at about $551,000. Geode Capital Management LLC purchased a new position in Acurx Pharmaceuticals during the 4th quarter valued at about $31,000. Finally, Jane Street Group LLC purchased a new position in Acurx Pharmaceuticals during the 4th quarter valued at about $27,000. 11.53% of the stock is currently owned by hedge funds and other institutional investors.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical?stage biopharmaceutical company focused on the discovery and development of novel anti?infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).